Transcatheter-Based Palliation of Congenital Heart Disease in Very Low Birth Weight Infants Authors: Connie Choi Published: 2026 ABSTRACT Corresponding AuthorKey Words: congenital heart defect, palliative care, ventricular septal defect The Need for Novel Interventions Premature infants born with very low birth weight (VLBW) (<1,500 g) have increasingly higher rates of survival and less morbidity.1, 2, 3, 4 However, patients with VLBW and congenital heart disease (CHD) continue to have a higher rate of mortality than those who do not have CHD.5,6 Patients with CHD have a higher mortality rate even when excluding those with significant chromosomal abnormalities.7 This suggests that palliation or repair of CHD may be important in improving outcomes for patients with VLBW and CHD. Small cohorts of surgical repair in this patient population have been reported with mixed results.8,9 Patients with VLBW still had higher rates of mortality and postoperative intracerebral hemorrhage compared with patients with low birth weight (LBW) who also underwent surgical CHD repair. The optimal timing of palliation or complete repair is still not known. Those who have deferred intervention may accrue complications from their unfavorable cardiac physiology and those who undergo intervention early may be at higher risk for procedural complications. The Changing Landscape of Pediatric Interventional Cardiology Devices for patent ductus arteriosus (PDA) closure in VLBW and LBW infants have recently been developed. Studies have shown that PDAs in these patients can be safely closed.10,11 As cardiac catheterizations in VLBW infants become increasingly the standard of care for this population, there has been growing experience in periprocedural management.12 This includes not only procedural technical expertise, but patient transport, anesthesia, and postprocedural care of this complex patient population. Transcatheter-based interventions other than PDA device closures are not routinely performed in VLBW patients; however, a growing number of studies are describing the feasibility of several different interventions.13, 14, 15 It is important for interventional colleagues to share their cases to build our collective experience. This is particularly valuable as many of the catheters and devices have not been developed for patients of this size. An Example of Successful Palliation In this issue of JACC: Case Reports, Krasic and Vukomanovic16 describe a case in which a VLBW infant with a PDA and large ventricular septal defect underwent a combination of PDA device closure and placement of bilateral branch pulmonary artery flow restrictors. Flow restrictors have been used for a number of diagnoses, but this is the first report of their use in a VLBW patient.17,18 The patient in this case study was extubated 5 days after the procedure and was discharged home a few weeks later. The patient ultimately had surgical ventricular septal defect closure and removal of flow restrictors without requiring additional pulmonary artery interventions. This is an example of effective palliation of a VLBW infant as a bridge to definitive repair. Importantly, the palliation did not result in a suboptimal definitive repair. Next Steps Additional studies need to be conducted to show feasibility and safety of transcatheter-based interventions in VLBW patients with CHD. Following feasibility studies, it will be important to show if patients are able to reach definitive repair with good outcomes and if there is a reduction in overall mortality in VLBW patients with CHD. Conclusions An increasing number of transcatheter-based interventions are being performed in VLBW patients with CHD. Further studies with larger cohorts of patients, different diagnoses of CHD and long-term outcome data are needed. Funding Support and Author Disclosures The author has reported that she has no relationships relevant to the contents of this paper to disclose. Footnotes The author attests they are in compliance with human studies committees and animal welfare regulations of the author’s institution and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References